Advertisement

Topics

Dynavax's experimental hepatitis B vaccine backed by FDA panel for licensing

05:17 EDT 1 Aug 2017 | SmartBrief

An FDA panel voted 11-1 to support licensing of Dynavax's Heplisav-B, a two-dose experimental vaccine for hepatitis B intende -More

Original Article: Dynavax's experimental hepatitis B vaccine backed by FDA panel for licensing

NEXT ARTICLE

More From BioPortfolio on "Dynavax's experimental hepatitis B vaccine backed by FDA panel for licensing"

Quick Search
Advertisement
 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Vaccine
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...